首页> 外文期刊>Plastic and reconstructive surgery >Blocking Bone Morphogenetic Protein Function Using In Vivo Noggin Therapy Does Not Rescue Premature Suture Fusion in Rabbits with Delayed-Onset Craniosynostosis.
【24h】

Blocking Bone Morphogenetic Protein Function Using In Vivo Noggin Therapy Does Not Rescue Premature Suture Fusion in Rabbits with Delayed-Onset Craniosynostosis.

机译:在体内Noggin疗法中阻断骨形态发生蛋白功能并不能拯救兔子的早产缝合融合,延迟发作的颅骨。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND:: Craniosynostosis is defined as the premature fusion of one or more cranial sutures. Bone morphogenetic proteins (BMPs), regulators of ossification, have been implicated in premature suture fusion. Noggin, an extracellular BMP inhibitor, has been shown experimentally to inhibit resynostosis following surgery. The present study was designed to test the hypothesis that BMP inhibition using noggin therapy may rescue sutures destined to fuse by inhibiting initial ossification. METHODS:: Twenty-six, 10-day old rabbits with familial, delayed-onset, coronal suture synostosis were randomly divided into three groups: (1) the sham surgical control group, (2) the bovine serum albumin-treated group [10 mug/suture (protein/vehicle controls)], and (3) the noggin therapy group (10 mug/suture; experimental group). Sutural growth was monitored by radiopaque markers implanted at 10 days of age. At 25 days, the bovine serum albumin or noggin was combined with a slow-resorbing collagen vehicle and injected subperiosteally above the coronal suture. Somatic and sutural growth data were collected at 10, 25, 42, and 84 days of age. Coronal sutures were harvested at 84 days to histologically assess fusion. RESULTS:: Results showed no significant (p > 0.05) differences in suture separation at any age. Suture fusion assessed by histomorphology did not differ among the three groups. Although previous data showed noggin to inhibit postoperative resynostosis in this craniosynostotic rabbit model, here there was no effect on initial suture fusion. CONCLUSION:: These results suggest that in this rabbit model of craniosynostosis, BMPs do not play a role in the pathogenesis of craniosynostosis and only play a role in postoperative bony wound healing.
机译:背景:: Craniosynostissis被定义为一个或多个颅缝的过早融合。骨形态发生蛋白(BMPS),骨化调节剂,在早产缝合融合中涉及。 Noggin是一种细胞外BMP抑制剂,已经通过实验显示,以抑制手术后的重新萎缩。本研究旨在测试使用Noggin治疗的BMP抑制可以通过抑制初始骨化来拯救注定熔断器的缝合线的假设。方法::二十六个,10天的兔子与家族性,延迟发作,冠状缝合线突触症随机分为三组:(1)假外科对照组,(2)牛血清白蛋白治疗组[10 MUG / SUTURE(蛋白质/型载体控制)]和(3)Noggin治疗组(10杯/缝合线;实验组)。在10天时植入的无线电泛动术标志物监测脉络膜生长。在25天时,将牛血清白蛋白或Noggin与缓慢再吸收的胶原蛋白,并在冠状缝合线上方注射亚尖峰。在10,25,42和84天内收集体细胞和脉络膜生长数据。在84天内收获冠状缝合线以组织学评估融合。结果::结果表明,在任何年龄的缝合分离中没有显着(p> 0.05)差异。通过组织形态学评估的缝合融合在三组中没有差异。尽管以前的数据显示Noggin在这种颅骨兔模型中抑制术后重新萎缩,但在此没有对初始缝合融合的影响。结论::这些结果表明,在这一兔子的抗皱症模型中,BMP不会在颅骨癌的发病机制中发挥作用,并且只在术后骨缠绕愈合中发挥作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号